New hope for relapsed and refractory multiple myeloma
Mené sur 457 patients atteints d'un myélome multiple réfractaire ou récidivant, cet essai international de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement combinant pomalidomide et dexaméthasone à faible dose avec un traitement par dexaméthasone à haute dose
Myeloma remains an incurable neoplasm despite the development of novel classes of drugs that have greatly prolonged survival of patients over the past 10 years. Patients with advanced refractory or relapsed and refractory myeloma who do not benefit from these newly developed proteasome inhibitors or immunomodulatory drugs have a median overall survival of only 9 months; this period is an important historical reference to improve for future drug development for patients with refractory or relapse ...
The Lancet Oncology , commentaire, 2012